UTILITY PATENT APPLICATION TRANSMITTAL

(only for new non-provisional applications under 37 CFR §1.53(b))

Mail Stop Patent Application Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

6.

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail in an envelope addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Bot 1450, Alexandria, VA 22313-1450, on November 12, 2003 Transmitted herewith for filing is the patent application under 37 CFR 1.53(b) of: AVENTIS DOCKET NO.: DEAV2002/0083 US NP INVENTORS: KOSTENIS, et al. **USE OF EDG2 RECEPTOR IN AN** TITLE: ANIMAL MODEL OF HEART FAILURE APPLICATION ELEMENTS *Fee Transmittal Form (e.g., PTO/SB/17) 1. (Submit an original and a duplicate for fee processing) Total Pages 29 2. Specification (preferred arrangement set forth below) - Descriptive title of the Invention - Cross References to Related Applications - Statement Regarding Fed sponsored R & D - Reference to Microfiche Appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure 4 3. Drawing(s) (35 U.S.C. 113) **Total Sheets** Total Pages Oath or Declaration 2 Newly unexecuted (original or copy) a. Copy from a prior application (37 CFR § 1.63(d)) b. **DELETION OF INVENTOR(S)** i. Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR §§ 1.63(d)(2) and 1.33(b). Total Pages 5. Power of Attorney Newly unexecuted (original or copy) Copy from a prior application (37 CFR § 1.63(d))

Microfiche Computer Program (Appendix)

Application Transmittal Letter Page 2

7.	Nucleotide and/or Amino Acid Sequence Submission- (if applicable, all necessary)									
	a. Computer Readable Copy									
	b. Apper Copy (identical to computer copy)									
	c. Statement verifying identity of above copies									
	If a CONTINUING Application, check appropriate box, and supply the requisite information: Continuation Divisional Continuation-in-part of prior application no: , filed , Examiner , Group/Art Unit . (The cross reference has been/will be inserted on page one of the specification).									
\boxtimes	This application claims the benefit of U.S. Provisional Application No. 60/455,231, filed March 17, 2003. (The cross reference has been/will be inserted on page one of the specification).									
	Incorporation By Reference (useable if filing a continuation/divisional and a copy of the declaration from the prior									
	application is enclosed.) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.									
ACC	OMPANYING APPLICATION PARTS									
7.	Assignment Papers (cover sheet & document(s))									
8.	37 CFR §3.73(b) Statement									
9.	(when there is an assignee) Verified English Translation Document (if applicable)									
3. 10.	Information Disclosure Copies of IDS Citations									
	Statement (IDS)/PTO-1449									
11.	Preliminary Amendment									
12.	Return Receipt Postcard (MPEP 503)									
13.	(Should be specifically itemized) *Small Entity Statement(s) Statement filed in prior application,									
13.	(PTO/SB/09-12) Status still proper and desired									
14.	Certified Copy of Priority Document(s)									
15.	EP 02025161.7 filed November 11, 2002 Other: Application Data Sheet									
10.	Application Data Sheet									
COF	RRESPONDENCE ADDRESS									
\square	Customer Number or Bar Code Label 005487									
	Customer Number of Bar Code Laber									
	(Insert Customer No. or Attach bar code label here)									
	h. haven Culterley									
	F. Aaron Dubberley, Reg. No. 41,001									
Aven	Attorney/Agent for Applicant tis Pharmaceuticals Inc.									

Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-3737
Telefax (908) 231-2626
Aventis Docket No. DEAV2002/0083 US NP

Approved for use through 04/30/2003. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

EEE TO A NOMITTAI	Complete if Known				
FEE TRANSMITTAL	Application Number	Not Yet Assigned			
f = T\/ 0000	Filing Date	November 12, 2003			
for FY 2003	First Named Inventor	KOSTENIS, et al.			
Patent fees are subject to annual revision.	Examiner Name	Not Yet Known			
Applicant claims small entity status. See 37 CFR 1.27	Group / Art Unit	Not Yet Known			
TOTAL AMOUNT OF PAYMENT (\$) 1,272.00	Attorney Docket No.	DEAV2002/0083 US NP			

METHOD OF PAYMENT (check all that apply)				FEE CALCULATION (continued)				
Check Credit Card Money Other None				DDITIO	NAL F	EES		
Order Deposit Account			Large E		Small E			
Deposit Account		10 1002	Fee Code	Fee (\$)	Fee Code	Fee (\$)		
Number Deposit	umber L 18-1702						Fee Description Fe	ee Paid
Account Name	Aven	itis Pharmaceuticals Inc.	1051	130	2051	65	Surcharge - late filing fee or oath	
The Commis		orized to: (check all that apply)					Surcharge - late provisional filing fee or	
	e(s) indicated belo	ow 🛛 Credit any overpayments	1052 1053	50 130	2052 1053	25 130	cover sheet Non-English Specification	
Charge any	y additional fee(s) during the pendency of this application	1812	2,520	1812	2,520	For filing a request for reexamination	
Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account				920*	1804	920*	Requesting publication of SIR prior to Examiner action	
FEE CALCULATION				1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1. BASIC F	ILING FEE		1251	110	2251	55	Extension for reply within first month	
Large Entity	Small Entity		1252	420	2252	205	Extension for reply within second month	
Fee Fee Code (\$)	Fee Fee Code (\$)							
1001 770	2001 375	, ,	1253	950	2253	465	Extension for reply within third month	
1002 340	2002 165		1254	1,480	2254	725	Extension for reply within fourth month	
1003 530	2003 260	•	1255	2,010	2255	985	Extension for reply within fifth month	
1004 770 1005 160	2004 375		1401	330	2401	160	Notice of Appeal	
1005 100	1		1402 1403	330 290	2402 2403	160	Filing a brief in support of an appeal	-
SUBTOTAL (1) (\$)770.00			<u> </u>			140	Request for oral hearing	
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE			1451	1,510	1451	1,510	Petition to institute a public use proceeding	
ĺ		Fee Extra from Fee	1452	110	2452	55	Petition to revive - unavoidable	
		Claims below Paid						
Total Claims	24 -20**=	4 x 18 = 72	1453	1,330	2453	650	Petition to revive - unintentional	
Independent	8 - 3**=	5 x 86 = 430	1501	1,330	2501	650	Utility issue fee (or reissue)	
Claims			1502	480	2502	235	Design issue fee	
Multiple Depend	ent	= 502	1503	640	2503	315	Plant issue fee	
Large Entity	Small Entity		1460 1807	130 50	1460 1807	130 50	Petitions to the Commissioner Petitions related to provisional	
Large Entity Fee Fee	Fee Fee		1007	30	1007	50	applications	
Code (\$)	Code (\$)		1806	180	1806	180	Submission of Information Disclosure	
1202 18	2202 9						Strnt	
1201 86	2201 42	Independent claims in excess of 3	8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1203 290	2203 140	Multiple dependent claim, if not paid	1809	770	2809	375	Filing a submission after final rejection (37 CFR § 1.129(a))	
1204 86	2204 42	•	1810	770	2810	375	For each additional invention to be examined (37 CFR § 1.129(b))	
1205 18			1801	770	2801	375	Request for Continued Examination (RCE)	
, 25 and 510. Siigindi patein			1802	900	1802	900	Request for expedited examination of a design application	
	SUBTO	ΓAL (2) (\$)502.00	Other fee	(specify)				_
**or number pr	eviously naid if r	greater: For Reissues, see above	*Reduce	d hy Basic	: Filing Fe	- Paid	SUBTOTAL (3) (\$)	
**or number previously paid, if greater; For Reissues, see above *Rei					, i mily ret	- r alu	SUBTOTAL (3) (\$)	

SUBMITTED BY		Complete (If applicable)				
Name (Print/Type)	F. Aaron Dubberley, Reg. No. 41,001	Registration No. (Attomey/Agent)	41,001	Telephone	(908) 231-3737	
Signature	To having Dulborley			Date		_

WARNING: Information on this form may become public. Credit card information should not be

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Alexandria, VA 22313. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.